Micro Cap Innovation Screener
Screening 235 names from $50M to $2B for patent activity, cash runway, revenue growth, and management quality. Includes the discovery cohort: main-universe stocks too young for a 200-week average, screened here until they earn one. 155 passed, 30 auto-rejected. Data as of 2026-11-14 13:59.
Read the 7-step methodology →155
Passed Screening
30
Red Flag Rejected
-
Score 8+
-
With Patents
| Ticker | Score | Patents | Runway | Rev Growth | Mkt Cap | Insider % | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| SGHT | 11/12 | 17 | 55mo | +25.2% | $601.9M | 35.2% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $88.4M Cash: $77.4M FCF: $-2.2M ROE: -50.1% • D/E: 86% Profit Margin: -32.1% Quality FCF insufficient_data Patents (17) • Controller for dry eye treatment systems • Devices and methods for intraocular tissue manipulation • Ocular delivery systems and methods +2 more — view all | ||||||||||
| KIDS | 11/12 | 13 | CF+ | +18.6% | $844.7M | 30.2% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $264.1M Cash: $44.2M FCF: $9.9M ROE: -9.8% • D/E: 33% Profit Margin: -12.8% Quality FCF+
Low Debt
FCF insufficient_data Patents (13) • Segmental tensioning of spinal tethers • Multiple track system for positioning of bone segments • Bone anchors with cord retention features +2 more — view all | ||||||||||
| HYLN | 10/12 | 23 | 16mo | +881.8% | $441.9M | 30.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $15.9M Cash: $54.6M FCF: $-33.5M ROE: -27.4% • D/E: 5% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (23) • Trailer-based energy capture and management • Engine apparatus and method for operation • Drive train configurations for a vehicle with multiple reversible engines +2 more — view all | ||||||||||
| ANGO | 10/12 | 28 | CF+ | +6.9% | $499.2M | 22.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $325.4M Cash: $34.0M FCF: $21.3M ROE: -19.2% • D/E: 6% Profit Margin: -10.1% Quality FCF+
Low Debt
FCF insufficient_data Patents (28) • Multiple treatment zone ablation probe • System and method for synchronizing energy delivery to the cardiac rhythm • Systems and methods for removing undesirable material within a circulatory system +2 more — view all | ||||||||||
| RNA | 10/12 | 21 | 35mo | +24.2% | $162.0M | 12.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 2/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $38.8M Cash: $232.1M FCF: $-60.4M ROE: -95.0% • D/E: 0% Profit Margin: -180.9% Quality Low Debt
FCF insufficient_data Patents (21) • Compositions and methods for treating ornithine transcarbamylase deficiency • Molecules and agents for treating hepatitis B virus • Coronavirus vaccine compositions and methods +2 more — view all | ||||||||||
| FHTX | 10/12 | 13 | 22mo | +924.7% | $124.1M | 56.4% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $112.1M Cash: $156.2M FCF: $-26.4M ROE: N/A • D/E: N/A Profit Margin: 8.4% Quality FCF insufficient_data Patents (13) • Compounds and uses thereof • Compounds and uses thereof • BRD9 degraders and uses thereof +2 more — view all | ||||||||||
| SMRT | 10/12 | 4 | CF+ | +14.8% | $301.8M | 11.2% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $156.6M Cash: $89.2M FCF: $8.2M ROE: -7.6% • D/E: 2% Profit Margin: -11.0% Quality FCF+
Low Debt
FCF insufficient_data Patents (4) | ||||||||||
| CTKB | 10/12 | 11 | 466mo | +1.8% | $763.8M | 19.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $207.6M Cash: $255.9M FCF: $8.6M ROE: -23.2% • D/E: 8% Profit Margin: -39.1% Quality FCF+
Low Debt
FCF insufficient_data Patents (11) • Cell sorter with pivotal scuppers • Smart flow cytometers with self monitoring fluidics • Methods of forming multi-color fluorescence-based flow cytometry panel +2 more — view all | ||||||||||
| EDIT | 9/12 | 23 | 21mo | +37.4% | $334.9M | 24.7% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $49.8M Cash: $190.2M FCF: $-34.0M ROE: -147.4% • D/E: 16% Profit Margin: -145.0% Quality Low Debt
FCF insufficient_data Patents (23) • Systems and methods for the treatment of hemoglobinopathies • Assessing nuclease cleavage • CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) +2 more — view all | ||||||||||
| KRMD | 9/12 | 2 | CF+ | +11.2% | $160.5M | 27.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $46.3M Cash: $7.4M FCF: $-1.0M ROE: -4.6% • D/E: 18% Profit Margin: -1.8% Quality Low Debt
FCF insufficient_data Patents (2) • Needle insertion device • Needle insertion device | ||||||||||
| QUIK | 9/12 | 6 | CF+ | +153.2% | $175.8M | 9.0% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 3/3 •
Mgmt: 1/3 Financials Revenue: $19.4M Cash: $19.2M FCF: $5.8M ROE: -32.3% • D/E: 25% Profit Margin: -57.8% Quality FCF+
Low Debt
FCF insufficient_data Patents (6) • Programmable logic device with design for test functionality • Sectional configuration for programmable logic devices • Programmable logic device with design for test functionality +2 more — view all Red Flags SBC_HIGH (54% of revenue) | ||||||||||
| NNDM | 9/12 | 15 | 72mo | +18.7% | $245.8M | 7.3% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 1/3 Financials Revenue: $125.9M Cash: $395.4M FCF: $-13.0M ROE: -30.3% • D/E: 1% Profit Margin: -118.4% Quality Low Debt
FCF insufficient_data Patents (15) • Electromagnetic band gap element structure and fabrication methods • Systems and methods for additive manufacturing passive resistor-capacitor frequency pass filter (PRC FPF) • System and method for mimicking a neural network without access to the original training dataset or the target model +2 more — view all Red Flags SBC_HIGH (66% of revenue) | ||||||||||
| ALLT | 9/12 | 3 | CF+ | +15.3% | $392.0M | 35.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $109.0M Cash: $102.2M FCF: $19.7M ROE: 9.4% • D/E: 6% Profit Margin: 9.4% Quality FCF+
Low Debt
FCF insufficient_data Patents (3) • Method, system, and device of cellular traffic monitoring • System, device, and method of protecting electronic devices against fraudulent and malicious activities • System, method, and apparatus of securing and managing internet-connected devices and networks | ||||||||||
| LUNG | 9/12 | 18 | 25mo | +6.2% | $124.6M | 12.3% | ||||
Score Breakdown Patents: 3/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $88.8M Cash: $52.7M FCF: $-9.5M ROE: -90.3% • D/E: 165% Profit Margin: -47.9% Quality FCF insufficient_data Patents (18) • Devices and systems for lung treatment • Methods and systems for endobronchial diagnostics • Methods, systems, and devices for analyzing lung imaging data +2 more — view all | ||||||||||
| RELL | 9/12 | 7 | CF+ | +18.9% | $270.0M | 4.6% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $238.9M Cash: $36.9M FCF: $-1.5M ROE: 5.2% • D/E: 2% Profit Margin: 3.6% Quality Low Debt
FCF insufficient_data Patents (7) • Hybrid capacitor energy storage • Resistor • Ultracapacitor generator start module +2 more — view all | ||||||||||
| AIRG | 9/12 | 18 | 37mo | +9.3% | $52.5M | 19.3% | ||||
Score Breakdown Patents: 3/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $52.7M Cash: $7.7M FCF: $-2.2M ROE: -22.3% • D/E: 14% Profit Margin: -12.6% Quality Low Debt
FCF insufficient_data Patents (18) • Multi-band MIMO repeater system with carrier aggregation capability • Antenna assembly for a vehicle • Antenna assembly for a vehicle with sleep sense command +2 more — view all | ||||||||||
| ARBE | 9/12 | 6 | 12mo | +156.6% | $56.3M | 16.1% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $1.9M Cash: $41.6M FCF: $-38.4M ROE: -83.2% • D/E: 64% Profit Margin: N/A Quality FCF insufficient_data Patents (6) • Method for separating targets and clutter from noise, in radar signals • Apparatus and method of two-stage signal processing in a radar system • Apparatus and method of eliminating settling time delays in a radar system +2 more — view all | ||||||||||
| UEIC | 9/12 | 135 | CF+ | -1.2% | $88.4M | 22.5% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $329.4M Cash: $41.4M FCF: $19.1M ROE: -5.0% • D/E: 20% Profit Margin: -2.2% Quality FCF+
Low Debt
FCF insufficient_data Patents (135) • System and method for a self adaptive multi-user program guide • Systems and methods for a customized media access user experience with privacy settings • Controlling device configurable to enable selection of one or more services +2 more — view all | ||||||||||
| YEXT | 9/12 | 24 | CF+ | -1.8% | $759.2M | 34.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $443.0M Cash: $86.8M FCF: $41.9M ROE: 27.8% • D/E: 622% Profit Margin: 5.9% Quality FCF+
High ROE
Wide Moat
FCF insufficient_data Patents (24) • Electronic device display or portion thereof with a graphical user interface • Online review generation using a redirection container • Online merchant review system and method utilizing dynamic URL redirection for distributing review requests +2 more — view all | ||||||||||
| EGHT | 9/12 | 112 | CF+ | +4.3% | $337.0M | 4.8% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $752.5M Cash: $101.7M FCF: $76.0M ROE: 5.1% • D/E: 228% Profit Margin: 1.0% Quality FCF+
FCF insufficient_data Patents (112) • Server-based service configuration system and approach • Management of VoIP device contact lists in a data communications services system • Analysis of customer interaction metrics from digital voice data in a data-communication server system +2 more — view all | ||||||||||
| AEYE | 9/12 | 5 | CF+ | +7.2% | $170.9M | 28.8% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $42.7M Cash: $9.3M FCF: $6.9M ROE: -56.7% • D/E: 326% Profit Margin: -7.1% Quality FCF+
FCF insufficient_data Patents (5) • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies • Modular systems and methods for selectively enabling cloud-based assistive technologies +2 more — view all | ||||||||||
| GEVO | 9/12 | 6 | CF+ | +94.2% | $452.7M | 7.7% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 3/3 •
Mgmt: 1/3 Financials Revenue: $217.8M Cash: $67.6M FCF: $-17.1M ROE: -45.6% • D/E: 56% Profit Margin: -83.7% Quality FCF insufficient_data Patents (6) • Selective formation of jet and diesel fuels from bio-based C3-C8 olefins via oligomerization with tungstated catalysts • Simultaneous dehydration, dimerization, and metathesis of C2-C5 alcohols • Upgrading of fusel oils over doped alumina +2 more — view all Red Flags SBC_HIGH (98% of revenue) | ||||||||||
| CLPT | 9/12 | 13 | 17mo | +36.3% | $271.8M | 18.5% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $45.5M Cash: $46.2M FCF: $-15.3M ROE: -167.5% • D/E: 270% Profit Margin: -79.4% Quality FCF insufficient_data Patents (13) • Automatic, patient-specific targeting for deep brain stimulation • Patient-specific infusion coverage estimates using segmented 3D brain representations • Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods +2 more — view all | ||||||||||
| ELMD | 9/12 | 1 | CF+ | +10.6% | $198.8M | 17.6% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $75.6M Cash: $15.9M FCF: $4.4M ROE: 24.5% • D/E: 0% Profit Margin: 15.8% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data Patents (1) • Body pulsating apparatus and method | ||||||||||
| APYX | 9/12 | 7 | 33mo | +22.1% | $118.4M | 27.6% | ||||
Score Breakdown Patents: 2/3 •
Runway: 2/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $58.4M Cash: $27.6M FCF: $-9.6M ROE: -90.7% • D/E: 357% Profit Margin: -14.8% Quality FCF insufficient_data Patents (7) • Devices, systems and methods for enhancing physiological effectiveness of medical cold plasma discharges • Electrosurgical apparatus with dynamic leakage current compensation and dynamic RF modulation • Skin status monitor and method thereof for electrosurgical apparatuses +2 more — view all | ||||||||||
| AVXL | 9/12 | 11 | 48mo | - | $86.5M | 3.1% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $0.0M Cash: $118.3M FCF: $-27.1M ROE: -12.8% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (11) • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy • Neurodevelopmental disorder therapy • Enantiomers of A2-73, analogues, and sigma agonist activity +2 more — view all | ||||||||||
| AUTL | 9/12 | 0 | CF+ | +94.6% | $311.4M | 55.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $137.4M Cash: $248.4M FCF: N/A ROE: -174.9% • D/E: 1449% Profit Margin: -186.4% Quality FCF insufficient_data | ||||||||||
| TMCI | 9/12 | 50 | 55mo | -3.9% | $345.5M | 26.4% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $203.3M Cash: $39.8M FCF: $-2.4M ROE: -74.0% • D/E: 121% Profit Margin: -27.4% Quality FCF insufficient_data Patents (50) • Cut guide with integrated joint realignment features • Contoured bone plate with locking screw for bone compression, particularly across a tarsometatarsal joint • Bone positioning and preparing guide systems and methods +2 more — view all | ||||||||||
| FDMT | 9/12 | 4 | 22mo | +4505.6% | $689.5M | 23.0% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $96.1M Cash: $307.0M FCF: $-93.8M ROE: -56.7% • D/E: 11% Profit Margin: -208.6% Quality Low Debt
FCF insufficient_data Patents (4) • Adeno-associated virus variant capsids and use for inhibiting angiogenesis • Adeno-associated virus variant capsids and methods of use thereof • Adeno-associated variants, formulations and methods for pulmonary delivery +1 more — view all | ||||||||||
| OVID | 9/12 | 12 | 28mo | - | $479.4M | 16.9% | ||||
Score Breakdown Patents: 3/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $1.5M Cash: $136.6M FCF: $-34.8M ROE: -35.4% • D/E: 6% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (12) • Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders • Methods of treating developmental disorders with gaboxadol • Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders +2 more — view all | ||||||||||
| XRX | 9/12 | 554 | CF+ | -4.7% | $125.5M | 12.5% | ||||
Score Breakdown Patents: 3/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $7664.0M Cash: $412.0M FCF: $398.5M ROE: -1673.8% • D/E: N/A Profit Margin: -15.4% Quality FCF+
FCF insufficient_data Patents (554) • Characterizing meniscus behavior in 3D liquid metal printing • Display screen with icon • Printer jetting mechanism and printer employing the printer jetting mechanism +2 more — view all | ||||||||||
| MASS | 8/12 | 0 | CF+ | +35.3% | $405.0M | 31.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $65.8M Cash: $99.1M FCF: $-17.8M ROE: -16.8% • D/E: 3% Profit Margin: -36.9% Quality Low Debt
FCF insufficient_data | ||||||||||
| PUBM | 8/12 | 0 | CF+ | +17.1% | $944.7M | 10.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $300.8M Cash: $144.5M FCF: $52.3M ROE: -0.6% • D/E: 16% Profit Margin: -0.5% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| OSPN | 8/12 | 2 | CF+ | +12.0% | $823.1M | 1.9% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $253.2M Cash: $51.4M FCF: $39.4M ROE: 26.8% • D/E: 5% Profit Margin: 27.5% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data Patents (2) • Blockchain-enhanced proof of identity • Blockchain-enhanced proof of identity | ||||||||||
| POWW | 8/12 | 0 | CF+ | +22.1% | $265.8M | 16.4% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $53.7M Cash: $68.8M FCF: $11.2M ROE: 2.0% • D/E: 5% Profit Margin: 12.1% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| CRNC | 8/12 | 1 | CF+ | +11.8% | $358.2M | 4.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $309.5M Cash: $127.6M FCF: $70.7M ROE: -9.6% • D/E: 112% Profit Margin: -5.0% Quality FCF+
FCF insufficient_data Patents (1) • Voice assistant error detection system | ||||||||||
| STXS | 8/12 | 0 | CF+ | +19.6% | $85.0M | 34.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $31.5M Cash: $4.0M FCF: N/A ROE: -117.4% • D/E: 30% Profit Margin: -70.9% Quality Low Debt
FCF insufficient_data | ||||||||||
| WEAV | 8/12 | 0 | CF+ | +15.5% | $595.3M | 26.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $257.8M Cash: $78.5M FCF: $39.4M ROE: -25.1% • D/E: 60% Profit Margin: -8.0% Quality FCF+
FCF insufficient_data | ||||||||||
| CXDO | 8/12 | 0 | CF+ | +43.9% | $164.2M | 31.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $88.6M Cash: $22.8M FCF: $10.5M ROE: 5.6% • D/E: 7% Profit Margin: 4.5% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| CODA | 8/12 | 3 | CF+ | +9.2% | $97.3M | 44.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $28.6M Cash: $31.8M FCF: $3.9M ROE: 8.4% • D/E: 1% Profit Margin: 17.6% Quality FCF+
Low Debt
FCF insufficient_data Patents (3) • Technologies for dynamic, real-time, four-dimensional volumetric multi-object underwater scene segmentation • Method of stabilizing sonar images • Combined method of location of sonar detection device | ||||||||||
| GSIT | 8/12 | 29 | 33mo | -6.6% | $118.8M | 15.0% | ||||
Score Breakdown Patents: 3/3 •
Runway: 2/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $24.7M Cash: $69.2M FCF: $-15.2M ROE: -31.5% • D/E: 10% Profit Margin: -79.5% Quality Low Debt
FCF insufficient_data Patents (29) • In memory matrix multiplication and its usage in neural networks • Reference distance similarity search • Memory device for determining an extreme value +2 more — view all | ||||||||||
| DUOT | 8/12 | 0 | CF+ | +29.5% | $158.1M | 20.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $26.7M Cash: $112.3M FCF: $-103.1M ROE: 36.0% • D/E: 0% Profit Margin: 150.5% Quality Low Debt
High ROE
FCF insufficient_data | ||||||||||
| PRQR | 8/12 | 0 | 29mo | +120.4% | $199.3M | 35.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $18.4M Cash: $117.1M FCF: $-19.1M ROE: -57.4% • D/E: 19% Profit Margin: -228.2% Quality Low Debt
FCF insufficient_data | ||||||||||
| RMNI | 8/12 | 1 | CF+ | +8.3% | $512.6M | 55.0% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $438.4M Cash: $94.3M FCF: $31.0M ROE: N/A • D/E: N/A Profit Margin: 2.5% Quality FCF+
FCF insufficient_data Patents (1) • Method and system for proactive client relationship analysis | ||||||||||
| CGEN | 8/12 | 0 | CF+ | +102.1% | $198.9M | 0.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 3/3 •
Mgmt: 2/3 Financials Revenue: $75.9M Cash: $117.5M FCF: N/A ROE: 57.2% • D/E: 3% Profit Margin: 47.9% Quality Low Debt
High ROE
Wide Moat
FCF insufficient_data | ||||||||||
| FLGT | 8/12 | 1 | CF+ | +7.5% | $689.0M | 38.7% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $330.3M Cash: $292.7M FCF: $9.7M ROE: -8.7% • D/E: 1% Profit Margin: -27.5% Quality FCF+
Low Debt
FCF insufficient_data Patents (1) • Nanoparticles containing a taxane and their use | ||||||||||
| BKTI | 8/12 | 2 | CF+ | +3.6% | $231.9M | 25.3% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $91.5M Cash: $29.2M FCF: $5.2M ROE: 28.6% • D/E: 2% Profit Margin: 15.2% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data Patents (2) • System and method for managing access to a push-to-talk-over-cellular communication network • System and method for managing access to a push-to-talk-over-cellular communication network | ||||||||||
| NNBR | 8/12 | 0 | CF+ | +26.2% | $285.0M | 23.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $483.0M Cash: $12.3M FCF: $5.9M ROE: -17.5% • D/E: 156% Profit Margin: -5.4% Quality FCF+
FCF insufficient_data | ||||||||||
| EOLS | 8/12 | 0 | 189mo | +13.0% | $460.7M | 27.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $325.5M Cash: $41.7M FCF: $13.4M ROE: N/A • D/E: N/A Profit Margin: -9.6% Quality FCF+
FCF insufficient_data | ||||||||||
| BCYC | 8/12 | 0 | 32mo | +190.2% | $236.2M | 84.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $83.5M Cash: $469.9M FCF: $-61.7M ROE: -25.2% • D/E: 3% Profit Margin: -169.8% Quality Low Debt
FCF insufficient_data | ||||||||||
| SEER | 8/12 | 8 | CF+ | -3.4% | $87.6M | 27.7% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $14.1M Cash: $155.9M FCF: N/A ROE: -26.2% • D/E: 10% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (8) • Compositions, methods and systems for protein corona analysis and uses thereof • Systems and methods for sample preparation, data generation, and protein corona analysis • Compositions, methods and systems for protein corona analysis and uses thereof +2 more — view all | ||||||||||
| IPHA | 8/12 | 16 | 3mo | +16.5% | $154.1M | 38.3% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $9.8M Cash: $10.9M FCF: $-29.0M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (16) • Variable regions for NKp46 binding proteins • Treatment of peripheral T cell lymphoma • NKp46 binding agents +2 more — view all | ||||||||||
| ZVIA | 8/12 | 0 | CF+ | +18.4% | $78.0M | 30.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $177.3M Cash: $29.5M FCF: $9.8M ROE: -25.7% • D/E: 1% Profit Margin: -4.8% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| CURV | 8/12 | 5 | 390mo | -11.8% | $226.4M | 73.9% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $948.8M Cash: $22.0M FCF: $21.9M ROE: N/A • D/E: N/A Profit Margin: -0.9% Quality FCF+
FCF insufficient_data Patents (5) • Wire-free push-up brassiere with hinge for improved support and flexibility • Power mesh panels for tummy-covering garments • Wire-free push-up brassiere with hinge for improved support and flexibility +2 more — view all | ||||||||||
| CURI | 8/12 | 0 | CF+ | +12.9% | $185.7M | 31.6% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $78.3M Cash: $7.0M FCF: $31.0M ROE: 19.3% • D/E: 8% Profit Margin: 11.0% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data | ||||||||||
| FBIO | 8/12 | 0 | CF+ | +14.0% | $62.7M | 36.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $68.5M Cash: $196.6M FCF: $-17.1M ROE: 116.0% • D/E: 26% Profit Margin: 163.3% Quality Low Debt
High ROE
Wide Moat
FCF insufficient_data | ||||||||||
| PERF | 8/12 | 1 | CF+ | - | $202.7M | 57.0% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $71.1M Cash: $162.0M FCF: $5.5M ROE: 3.8% • D/E: 0% Profit Margin: 8.1% Quality FCF+
Low Debt
FCF insufficient_data Patents (1) • Blender including an integrated smart scale and a recipe application | ||||||||||
| SMC | 8/12 | 0 | CF+ | +24.6% | $620.0M | 77.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $620.4M Cash: $12.5M FCF: $-36.1M ROE: -0.6% • D/E: 134% Profit Margin: -0.6% Quality FCF insufficient_data | ||||||||||
| ELMT | 8/12 | 0 | 28mo | +55.6% | $608.0M | 67.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 3/3 •
Mgmt: 3/3 Financials Revenue: $257.0M Cash: $112.3M FCF: $-193.8M ROE: 2.2% • D/E: 12% Profit Margin: 1.5% Quality Low Debt
FCF insufficient_data | ||||||||||
| RNGR | 8/12 | 0 | CF+ | +26.3% | $296.5M | 21.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $640.6M Cash: $6.0M FCF: $1.6M ROE: 5.4% • D/E: 11% Profit Margin: 2.4% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| LAB | 8/12 | 4 | 86mo | -0.9% | $279.3M | 52.4% | ||||
Score Breakdown Patents: 2/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $84.4M Cash: $461.1M FCF: $179.6M ROE: -7.8% • D/E: 5% Profit Margin: 157.6% Quality FCF+
Low Debt
FCF insufficient_data Patents (4) • Scientific instrument • Parallelized sample processing and library prep • Parallelized sample processing and library prep +1 more — view all | ||||||||||
| SHIP | 8/12 | 0 | CF+ | +22.3% | $344.7M | 27.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $204.7M Cash: $167.9M FCF: N/A ROE: 24.6% • D/E: 123% Profit Margin: 36.3% Quality High ROE
Wide Moat
FCF insufficient_data | ||||||||||
| PROF | 7/12 | 8 | 13mo | +12.3% | $271.8M | 3.1% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $19.1M Cash: $38.3M FCF: $-24.8M ROE: -73.5% • D/E: 15% Profit Margin: -171.6% Quality Low Debt
FCF insufficient_data Patents (8) • Multi-channel real-time phase modulation for EMI reduction in an ultrasound device • System and method for open-loop ultrasound therapy to the prostate including restricting the therapy delivered to a predetermined angular range • Ultrasonic therapy applicator and method of determining position of ultrasound transducers +2 more — view all | ||||||||||
| EGAN | 7/12 | 1 | CF+ | -7.0% | $156.9M | 48.2% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $89.5M Cash: $71.3M FCF: N/A ROE: 9.1% • D/E: 3% Profit Margin: 8.5% Quality Low Debt
FCF insufficient_data Patents (1) • System and method for automatic agent assistance based on real-time metrics | ||||||||||
| PSFE | 7/12 | 0 | CF+ | +1.3% | $210.2M | 53.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $1768.1M Cash: $250.7M FCF: $172.4M ROE: -70.5% • D/E: 769% Profit Margin: -20.8% Quality FCF+
FCF insufficient_data | ||||||||||
| PACB | 7/12 | 59 | 18mo | +5.5% | $612.0M | 1.9% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $161.4M Cash: $199.4M FCF: $44.1M ROE: N/A • D/E: N/A Profit Margin: -81.3% Quality FCF+
FCF insufficient_data Patents (59) • Methods and compositions for sequencing double stranded nucleic acids • Protected dye-labeled reagents • High speed scanning system with acceleration tracking +2 more — view all | ||||||||||
| LTBR | 7/12 | 0 | 146mo | - | $158.9M | 12.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $236.7M FCF: $-10.8M ROE: -14.1% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data | ||||||||||
| HYPR | 7/12 | 1 | 16mo | +73.4% | $66.7M | 4.9% | ||||
Score Breakdown Patents: 1/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 2/3 Financials Revenue: $19.1M Cash: $37.9M FCF: $-17.0M ROE: -101.7% • D/E: 44% Profit Margin: -156.4% Quality Low Debt
FCF insufficient_data Patents (1) • Suppressing image artifact with RF pulse phase in multi-shot SS-FSE sequence | ||||||||||
| AVNW | 7/12 | 2 | CF+ | -5.0% | $224.1M | 10.9% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $434.3M Cash: $55.4M FCF: $9.6M ROE: -0.2% • D/E: 34% Profit Margin: -0.1% Quality FCF+
Low Debt
FCF insufficient_data Patents (2) • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing • Resilient data communications with physical layer link aggregation, extended failure detection and load balancing | ||||||||||
| TATT | 7/12 | 0 | CF+ | +20.2% | $488.7M | 0.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $196.2M Cash: $53.7M FCF: $-4.3M ROE: 13.0% • D/E: 8% Profit Margin: 12.2% Quality Low Debt
FCF insufficient_data | ||||||||||
| WRAP | 7/12 | 13 | 6mo | +102.8% | $91.8M | 38.5% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 3/3 •
Mgmt: 1/3 Financials Revenue: $6.1M Cash: $4.8M FCF: $-4.4M ROE: -107.7% • D/E: 3% Profit Margin: -223.1% Quality Low Debt
FCF insufficient_data Patents (13) • Projectile cassette • Systems and methods for generating optical beam arrays • Projectile anchor +2 more — view all Red Flags SBC_HIGH (91% of revenue) | ||||||||||
| SSTI | 7/12 | 1 | CF+ | -0.4% | $109.4M | 46.3% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $97.9M Cash: $9.6M FCF: $8.2M ROE: -34.6% • D/E: 10% Profit Margin: -23.5% Quality FCF+
Low Debt
FCF insufficient_data Patents (1) • Systems and methods for weapon and destructive device detection based on electromagnetic field profile | ||||||||||
| OPAL | 7/12 | 2 | CF+ | -4.6% | $212.4M | 44.4% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $336.0M Cash: $88.1M FCF: $-36.4M ROE: 8.9% • D/E: 87% Profit Margin: 7.8% Quality FCF insufficient_data Patents (2) • Defuel priority panel • Modular and portable compressed natural gas fueling station | ||||||||||
| BLZE | 7/12 | 0 | CF+ | +25.5% | $489.2M | 4.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $165.8M Cash: $230.2M FCF: $45.4M ROE: -23.2% • D/E: 353% Profit Margin: -11.5% Quality FCF+
FCF insufficient_data | ||||||||||
| RBBN | 7/12 | 1 | 26mo | +1.6% | $263.4M | 48.4% | ||||
Score Breakdown Patents: 1/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $801.0M Cash: $40.4M FCF: $8.0M ROE: 5.0% • D/E: 105% Profit Margin: 2.3% Quality FCF+
FCF insufficient_data Patents (1) • Telecommunication call emulation | ||||||||||
| SMWB | 7/12 | 0 | CF+ | +8.8% | $703.3M | 51.6% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $295.6M Cash: $73.9M FCF: $29.1M ROE: -94.0% • D/E: 201% Profit Margin: -7.4% Quality FCF+
FCF insufficient_data | ||||||||||
| SIGA | 7/12 | 3 | 121mo | -49.7% | $196.9M | 42.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $52.4M Cash: $116.4M FCF: $-11.7M ROE: 0.4% • D/E: 0% Profit Margin: 1.3% Quality Low Debt
FCF insufficient_data Patents (3) • Polymorphic forms of ST-246 and methods of preparation • ST-246 (tecovirimat monohydrate) suspension formulations • Polymorphic forms of ST-246 and methods of preparation | ||||||||||
| GDYN | 7/12 | 0 | CF+ | +9.7% | $1061.7M | 31.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $432.7M Cash: $304.3M FCF: $36.5M ROE: 1.5% • D/E: 3% Profit Margin: 1.8% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| DERM | 7/12 | 1 | 31mo | +7.6% | $122.2M | 29.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $69.5M Cash: $22.3M FCF: $-6.1M ROE: -17.6% • D/E: 79% Profit Margin: -7.3% Quality FCF insufficient_data Patents (1) • Topical tetracycline compositions | ||||||||||
| ORMP | 7/12 | 0 | 204mo | - | $161.3M | 28.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $53.8M FCF: $-0.4M ROE: 53.5% • D/E: 0% Profit Margin: N/A Quality Low Debt
High ROE
FCF insufficient_data | ||||||||||
| RPAY | 7/12 | 0 | CF+ | +97.4% | $397.2M | 52.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 3/3 •
Mgmt: 1/3 Financials Revenue: $413.5M Cash: $63.8M FCF: $32.7M ROE: -33.2% • D/E: 166% Profit Margin: -41.2% Quality FCF+
FCF insufficient_data Red Flags SBC_HIGH (63% of revenue) | ||||||||||
| PMVP | 7/12 | 8 | 18mo | - | $95.9M | 21.7% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $102.6M FCF: $-42.7M ROE: -99.4% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (8) • Methods and compounds for restoring mutant p53 function • Deuterated compounds for restoring mutant p53 function • Methods and compounds for restoring mutant p53 function +2 more — view all | ||||||||||
| PLBY | 7/12 | 0 | 58mo | +9.4% | $150.1M | 43.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $128.1M Cash: $29.7M FCF: $8.2M ROE: 10.7% • D/E: 669% Profit Margin: 1.3% Quality FCF+
FCF insufficient_data | ||||||||||
| MNOV | 7/12 | 8 | 36mo | +12.4% | $71.5M | 12.8% | ||||
Score Breakdown Patents: 2/3 •
Runway: 2/3 •
Revenue: 2/3 •
Mgmt: 1/3 Financials Revenue: $0.9M Cash: $29.3M FCF: $-6.8M ROE: -24.8% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (8) • Methods of treating post-COVID condition(s) • Treatment of progressive neurodegenerative disease with ibudilast • Methods of reducing plasma level of macrophage migratory inhibitory factor in patients +2 more — view all Red Flags SBC_HIGH (80% of revenue) | ||||||||||
| XBIT | 7/12 | 3 | 32mo | - | $59.8M | 38.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $109.5M FCF: $-28.5M ROE: -29.9% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (3) • Arthritis treatment • Compositions and methods for treating and preventing Staphylococcus aureus infections • Treatment for neoplastic diseases | ||||||||||
| BRLT | 7/12 | 2 | CF+ | +2.3% | $125.7M | 10.0% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $451.8M Cash: $76.2M FCF: $8.6M ROE: -8.6% • D/E: 58% Profit Margin: -0.9% Quality FCF+
FCF insufficient_data Patents (2) • Ring • Bracelet | ||||||||||
| ASUR | 7/12 | 0 | CF+ | +10.4% | $313.5M | 8.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $159.2M Cash: $16.8M FCF: $15.9M ROE: -1.9% • D/E: 36% Profit Margin: -2.3% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| IIIN | 7/12 | 0 | CF+ | +17.9% | $540.0M | 4.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 2/3 •
Mgmt: 2/3 Financials Revenue: $739.5M Cash: $37.5M FCF: $19.1M ROE: 7.9% • D/E: 1% Profit Margin: 4.0% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| ALTO | 7/12 | 0 | CF+ | +7.0% | $283.9M | 10.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $960.2M Cash: $23.6M FCF: $3.0M ROE: 20.5% • D/E: 28% Profit Margin: 5.3% Quality FCF+
Low Debt
High ROE
Buffett
FCF insufficient_data | ||||||||||
| NEXN | 7/12 | 0 | CF+ | +8.6% | $587.7M | 14.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $391.0M Cash: $152.9M FCF: $70.8M ROE: 4.0% • D/E: 8% Profit Margin: 4.9% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| FATE | 6/12 | 18 | 16mo | - | $155.7M | 11.8% | ||||
Score Breakdown Patents: 3/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $4.8M Cash: $139.1M FCF: $-50.7M ROE: -67.8% • D/E: 56% Profit Margin: N/A Quality FCF insufficient_data Patents (18) • Combining iPSC derived effector cell types for immunotherapy use • Vial rack • Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs +2 more — view all Red Flags SBC_HIGH (399% of revenue) | ||||||||||
| AIRS | 6/12 | 0 | 92mo | -8.7% | $61.9M | 74.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $147.7M Cash: $15.2M FCF: $6.2M ROE: -10.0% • D/E: 61% Profit Margin: -6.4% Quality FCF+
FCF insufficient_data | ||||||||||
| SPWR | 6/12 | 21 | 1mo | -17.0% | $52.3M | 71.5% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $283.1M Cash: $4.1M FCF: $3.9M ROE: N/A • D/E: N/A Profit Margin: -3.8% Quality FCF+
FCF insufficient_data Patents (21) • Water sealing surface attachment • Systems and method for determining solar panel placement and energy output • Methods of recycling silicon swarf into electronic grade polysilicon or metallurgical-grade silicon +2 more — view all | ||||||||||
| HYSR | 6/12 | 0 | 72mo | - | $86.2M | 1.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $0.0M Cash: $30.5M FCF: $-3.8M ROE: -22.9% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| AIOT | 6/12 | 0 | CF+ | +3.6% | $327.9M | 7.4% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $454.5M Cash: $26.8M FCF: $24.0M ROE: -4.3% • D/E: 64% Profit Margin: -4.7% Quality FCF+
FCF insufficient_data | ||||||||||
| TTGT | 6/12 | 0 | CF+ | -2.5% | $204.5M | 70.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $482.1M Cash: $35.3M FCF: $57.1M ROE: -22.1% • D/E: 27% Profit Margin: -24.9% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| DOMO | 6/12 | 0 | 504mo | -3.7% | $167.0M | 16.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $315.2M Cash: $25.1M FCF: $10.9M ROE: N/A • D/E: N/A Profit Margin: -13.4% Quality FCF+
FCF insufficient_data | ||||||||||
| XNET | 6/12 | 0 | CF+ | -1.4% | $218.6M | 55.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $493.4M Cash: $276.9M FCF: N/A ROE: -8.9% • D/E: 6% Profit Margin: -14.5% Quality Low Debt
FCF insufficient_data | ||||||||||
| NKTX | 6/12 | 3 | 19mo | - | $85.2M | 15.3% | ||||
Score Breakdown Patents: 1/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $156.6M FCF: $-59.3M ROE: -46.6% • D/E: 33% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (3) • Immune cells comprising truncated NKG2D chimeric receptors • Genetically modified natural killer cells for CD70-directed cancer immunotherapy • CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | ||||||||||
| RGNX | 6/12 | 6 | 20mo | -69.2% | $505.2M | 13.3% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $153.9M Cash: $251.0M FCF: $-128.9M ROE: -113.2% • D/E: 170% Profit Margin: -113.9% Quality FCF insufficient_data Patents (6) • Anion exchange chromatography for recombinant AAV production • Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) • Treatment of mucopolysaccharidosis IVA +2 more — view all | ||||||||||
| INFU | 6/12 | 0 | CF+ | +3.0% | $294.9M | 5.6% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $144.4M Cash: $9.1M FCF: $8.1M ROE: 15.8% • D/E: 37% Profit Margin: 6.5% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data | ||||||||||
| MBOT | 6/12 | 2 | 46mo | - | $65.7M | 0.0% | ||||
Score Breakdown Patents: 1/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $0.3M Cash: $67.4M FCF: $-14.2M ROE: -32.9% • D/E: 1% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (2) • Modular robotic system for driving movement of surgical tools • Device for automatically inserting and manipulating a medical tool into and within a bodily lumen | ||||||||||
| RCEL | 6/12 | 1 | 6mo | +53.1% | $491.1M | 1.5% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 3/3 •
Mgmt: 2/3 Financials Revenue: $84.7M Cash: $10.5M FCF: $-8.4M ROE: N/A • D/E: N/A Profit Margin: -42.7% Quality FCF insufficient_data Patents (1) • Tissue processing tray | ||||||||||
| FULC | 6/12 | 2 | 57mo | - | $288.0M | 16.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $306.5M FCF: $-41.2M ROE: -30.5% • D/E: 2% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (2) • Compositions and methods for modulating FMR1 expression • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Red Flags HYPE_PRICING ($0.0M rev, $288M mcap) | ||||||||||
| OPRX | 6/12 | 0 | CF+ | -29.8% | $138.3M | 23.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $98.7M Cash: $24.1M FCF: $15.8M ROE: 3.7% • D/E: 15% Profit Margin: 4.7% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| OKYO | 6/12 | 0 | 42mo | - | $70.8M | 46.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $20.6M FCF: $-2.1M ROE: -263.8% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data | ||||||||||
| STTK | 6/12 | 9 | 48mo | - | $473.6M | 32.0% | ||||
Score Breakdown Patents: 2/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $196.3M FCF: $-25.0M ROE: -47.2% • D/E: 1% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (9) • Heterodimeric proteins and uses thereof • Fusion proteins for the treatment of cardiometabolic diseases • Antibodies that bind TNFRSF25 +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $474M mcap) | ||||||||||
| BWEN | 6/12 | 0 | CF+ | -49.7% | $56.1M | 13.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $148.9M Cash: $16.2M FCF: $7.0M ROE: -0.3% • D/E: 33% Profit Margin: -2.9% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| VYGR | 6/12 | 23 | 12mo | -70.0% | $107.7M | 27.9% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $25.1M Cash: $106.8M FCF: $-68.5M ROE: -58.9% • D/E: 23% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (23) • Compositions and methods for delivery of AAV • Redirection of tropism of AAV capsids • Treatment of amyotrophic lateral sclerosis (ALS) +2 more — view all | ||||||||||
| FATN | 6/12 | 0 | 15mo | +22.1% | $65.3M | 55.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 2/3 •
Mgmt: 3/3 Financials Revenue: $21.2M Cash: $3.1M FCF: $-2.0M ROE: 27.5% • D/E: 19% Profit Margin: 31.6% Quality Low Debt
High ROE
Wide Moat
FCF insufficient_data | ||||||||||
| CAN | 6/12 | 14 | 7mo | -68.2% | $115.5M | 18.9% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $441.3M Cash: $68.3M FCF: $-71.8M ROE: -97.1% • D/E: 24% Profit Margin: -67.8% Quality Low Debt
FCF insufficient_data Patents (14) • Cooling container for computing devices • Modular computing apparatus with integrated power and signal routing • Waste heat utilization system of immersed liquid cooling heat dissipation device +2 more — view all | ||||||||||
| SELF | 6/12 | 0 | CF+ | +0.6% | $55.4M | 8.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $12.8M Cash: $7.5M FCF: $3.3M ROE: 4.5% • D/E: 34% Profit Margin: 16.6% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| HOVR | 6/12 | 0 | 39mo | - | $85.2M | 18.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $70.1M FCF: $-15.1M ROE: -66.9% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| GRVY | 6/12 | 0 | CF+ | -4.6% | $492.0M | 59.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $562284.7M Cash: $654692.0M FCF: N/A ROE: 13.2% • D/E: 0% Profit Margin: 15.3% Quality Low Debt
FCF insufficient_data | ||||||||||
| PNRG | 6/12 | 0 | CF+ | -3.9% | $308.7M | 61.4% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $177.7M Cash: $28.7M FCF: $24.0M ROE: 11.7% • D/E: 0% Profit Margin: 14.0% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| REA | 6/12 | 0 | 40mo | - | $117.8M | 53.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $68.3M FCF: N/A ROE: N/A • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| GNE | 6/12 | 0 | CF+ | -8.0% | $481.6M | 17.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $491.5M Cash: $215.2M FCF: $31.3M ROE: 14.7% • D/E: 3% Profit Margin: 5.9% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| IONR | 6/12 | 1 | 115mo | - | $168.4M | 20.3% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.7M Cash: $58.8M FCF: N/A ROE: N/A • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (1) • Apparatus and method for determining parameters of process operation Red Flags SBC_HIGH (305% of revenue) | ||||||||||
| NUCL | 6/12 | 0 | 42mo | - | $110.4M | 56.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $28.1M FCF: $-3.0M ROE: -250.8% • D/E: 4% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| RXST | 5/12 | 2 | CF+ | -19.0% | $223.1M | 16.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $121.8M Cash: $254.7M FCF: $39.4M ROE: -20.1% • D/E: 4% Profit Margin: -43.8% Quality FCF+
Low Debt
FCF insufficient_data Patents (2) • Light adjustable intraocular lens with a modulable absorption front protection layer • Light adjustable intraocular lens with a modulable absorption front protection layer Red Flags SBC_HIGH (63% of revenue) | ||||||||||
| PERI | 5/12 | 0 | CF+ | -4.6% | $369.1M | -11.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 2/3 Financials Revenue: $436.2M Cash: $267.8M FCF: $55.1M ROE: -2.0% • D/E: 4% Profit Margin: -3.0% Quality FCF+
Low Debt
FCF insufficient_data | ||||||||||
| ZNTL | 5/12 | 0 | 20mo | - | $167.1M | 20.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $228.9M FCF: $-85.1M ROE: -61.9% • D/E: 18% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| BLNK | 5/12 | 1 | 64mo | -32.0% | $61.0M | 1.5% | ||||
Score Breakdown Patents: 1/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $87.9M Cash: $30.5M FCF: $16.8M ROE: -85.7% • D/E: 9% Profit Margin: -64.9% Quality FCF+
Low Debt
FCF insufficient_data Patents (1) • Self-aligning holster for J1772 plug used in electric vehicle supply equipment Red Flags SBC_HIGH (58% of revenue) | ||||||||||
| LRMR | 5/12 | 7 | 12mo | - | $313.7M | 44.3% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $156.3M FCF: $-94.2M ROE: -139.6% • D/E: 4% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (7) • Methods for treating myelin associated diseases and mitochondria associated diseases • Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof • Methods for quantifying frataxin activity +2 more — view all Red Flags HYPE_PRICING ($0.0M rev, $314M mcap) | ||||||||||
| HUMA | 5/12 | 4 | 9mo | +36.5% | $155.1M | 9.7% | ||||
Score Breakdown Patents: 2/3 •
Runway: 0/3 •
Revenue: 2/3 •
Mgmt: 1/3 Financials Revenue: $2.4M Cash: $64.5M FCF: $-56.1M ROE: -1423.6% • D/E: 368% Profit Margin: N/A Quality FCF insufficient_data Patents (4) • Fluid systems, apparatuses, devices and methods of management thereof for cultivating tissue • Tubular prostheses • Drawer system for cultivating tissue +1 more — view all Red Flags SBC_HIGH (268% of revenue) | ||||||||||
| PYPD | 5/12 | 1 | 3mo | - | $132.2M | 41.2% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $6.6M FCF: $-17.4M ROE: -243.6% • D/E: 29% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (1) • Compositions and methods for the treatment and prophylaxis of surgical site infections | ||||||||||
| ASRT | 5/12 | 0 | 121mo | -62.5% | $151.9M | 3.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 2/3 Financials Revenue: $102.2M Cash: $71.6M FCF: $7.8M ROE: -38.8% • D/E: 53% Profit Margin: -34.9% Quality FCF+
FCF insufficient_data | ||||||||||
| CGTX | 5/12 | 0 | 24mo | - | $64.6M | 8.0% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 1/3 •
Mgmt: 2/3 Financials Revenue: $0.0M Cash: $30.8M FCF: $-23.3M ROE: -48.6% • D/E: 2% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| CRBP | 5/12 | 0 | 15mo | - | $69.9M | 25.5% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $115.3M FCF: $-49.8M ROE: -131.5% • D/E: 5% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| TNYA | 5/12 | 10 | 15mo | - | $79.6M | 5.5% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $3.0M Cash: $66.8M FCF: $-29.8M ROE: -148.2% • D/E: 5% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (10) • Gene therapy vectors for treating heart disease • Cardiac cell reprogramming with myocardin and ASCL1 • Optimized expression cassettes for gene therapy +2 more — view all Red Flags SBC_HIGH (1562% of revenue) | ||||||||||
| PRLD | 5/12 | 0 | 55mo | - | $275.3M | 66.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $22.4M Cash: $151.8M FCF: $-13.8M ROE: -57.7% • D/E: 13% Profit Margin: -269.7% Quality Low Debt
FCF insufficient_data Red Flags SBC_HIGH (121% of revenue) | ||||||||||
| TLSA | 5/12 | 1 | 3mo | - | $72.5M | 49.6% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $3.2M FCF: $-6.4M ROE: -780.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | ||||||||||
| HNST | 5/12 | 0 | CF+ | -8.6% | $547.1M | 9.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 2/3 Financials Revenue: $334.1M Cash: $103.0M FCF: $70.1M ROE: 34.6% • D/E: 3% Profit Margin: 23.5% Quality FCF+
Low Debt
High ROE
Wide Moat
Buffett
FCF insufficient_data | ||||||||||
| UPB | 5/12 | 3 | 15mo | -42.2% | $152.4M | 21.8% | ||||
Score Breakdown Patents: 1/3 •
Runway: 1/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $2.9M Cash: $207.4M FCF: $-114.3M ROE: -53.5% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (3) • Pharmaceutical composition comprising anti-human TSLP receptor antibody • Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same • Pharmaceutical composition comprising anti-human TSLP receptor antibody | ||||||||||
| NPWR | 5/12 | 0 | 23mo | - | $169.6M | 47.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $182.9M FCF: $-78.6M ROE: -69.8% • D/E: 1% Profit Margin: N/A Quality Low Debt
FCF insufficient_data | ||||||||||
| SWMR | 5/12 | 0 | 21mo | +56.6% | $126.4M | 75.3% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 3/3 •
Mgmt: 1/3 Financials Revenue: $0.3M Cash: $25.3M FCF: N/A ROE: N/A • D/E: 1% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Red Flags SBC_HIGH (1230% of revenue) | ||||||||||
| IPSC | 4/12 | 3 | 17mo | - | $299.6M | 44.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $117.2M FCF: $-57.5M ROE: -51.2% • D/E: 18% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (3) • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Artificial cell death polypeptide for chimeric antigen receptor and uses thereof • Chimeric antigen receptor system with adaptable receptor specificity Red Flags HYPE_PRICING ($0.0M rev, $300M mcap) | ||||||||||
| VANI | 4/12 | 0 | 9mo | - | $91.1M | 56.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 3/3 Financials Revenue: $0.0M Cash: $19.9M FCF: $-16.8M ROE: -220.4% • D/E: 94% Profit Margin: N/A Quality FCF insufficient_data | ||||||||||
| VUZI | 4/12 | 33 | 4mo | -38.5% | $114.5M | 22.7% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $5.5M Cash: $9.2M FCF: $-17.5M ROE: -102.2% • D/E: 2% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (33) • Wearable mobile electronic system • Color correction for virtual images of near-eye displays • Smart glasses +2 more — view all Red Flags SBC_HIGH (135% of revenue) | ||||||||||
| INVZ | 4/12 | 22 | 11mo | -20.8% | $51.9M | 10.3% | ||||
Score Breakdown Patents: 3/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $50.0M Cash: $54.4M FCF: $-30.3M ROE: -114.2% • D/E: 56% Profit Margin: -171.2% Quality FCF insufficient_data Patents (22) • Systems and methods for photodiode-based detection • Efficient optical transmission in LIDAR systems • Distributing LIDAR system components +2 more — view all Red Flags SBC_HIGH (56% of revenue) | ||||||||||
| VITL | 4/12 | 0 | 21mo | -8.4% | $389.4M | 19.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $748.9M Cash: $84.0M FCF: $-77.0M ROE: -7.4% • D/E: 67% Profit Margin: -3.0% Quality FCF insufficient_data | ||||||||||
| CBUS | 4/12 | 1 | 3mo | +30.1% | $86.6M | 25.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 2/3 •
Mgmt: 1/3 Financials Revenue: $4.5M Cash: $10.7M FCF: $-49.9M ROE: -419.6% • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Patents (1) • Plant shade Red Flags SBC_HIGH (1169% of revenue) | ||||||||||
| DAVA | 4/12 | 0 | CF+ | -8.4% | $77.2M | 12.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $727.6M Cash: $48.4M FCF: $30.9M ROE: -99.8% • D/E: 138% Profit Margin: -56.1% Quality FCF+
FCF insufficient_data Red Flags SBC_HIGH (61% of revenue) | ||||||||||
| ADUR | 4/12 | 0 | 80mo | - | $348.8M | 29.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 3/3 •
Revenue: 1/3 •
Mgmt: 0/3 Financials Revenue: $0.1M Cash: $65.8M FCF: $-8.0M ROE: -48.3% • D/E: 1% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Red Flags SBC_HIGH (7738% of revenue)
HYPE_PRICING ($0.1M rev, $349M mcap) | ||||||||||
| SES | 4/12 | 0 | 28mo | -6.7% | $189.0M | 8.7% | ||||
Score Breakdown Patents: 0/3 •
Runway: 2/3 •
Revenue: 0/3 •
Mgmt: 2/3 Financials Revenue: $23.0M Cash: $137.3M FCF: $-38.2M ROE: -30.6% • D/E: 4% Profit Margin: -262.9% Quality Low Debt
FCF insufficient_data | ||||||||||
| IRD | 4/12 | 5 | 22mo | -63.1% | $384.7M | 12.5% | ||||
Score Breakdown Patents: 2/3 •
Runway: 1/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $7.9M Cash: $89.0M FCF: $-54.4M ROE: -615.6% • D/E: 93% Profit Margin: N/A Quality FCF insufficient_data Patents (5) • Salts and esters of APX3330 and therapeutic uses thereof • Methods and compositions for treatment of mydriasis • Aqueous ophthalmic solutions of phentolamine and medical uses thereof +2 more — view all Red Flags SBC_HIGH (1113% of revenue) | ||||||||||
| RCKT | 3/12 | 0 | 20mo | - | $256.8M | 20.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $269.5M FCF: $99.1M ROE: -5.0% • D/E: 17% Profit Margin: N/A Quality FCF+
Low Debt
FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $257M mcap) | ||||||||||
| CRDF | 3/12 | 3 | 10mo | -14.1% | $56.5M | 3.1% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 2/3 Financials Revenue: $0.5M Cash: $34.5M FCF: $-24.3M ROE: -94.1% • D/E: 2% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (3) • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer • Cancer treatment using FGFR inhibitors and PLK1 inhibitors | ||||||||||
| DMAC | 3/12 | 0 | 12mo | - | $474.3M | 53.1% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $34.9M FCF: $-19.0M ROE: -100.2% • D/E: 0% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $474M mcap) | ||||||||||
| NINE | 3/12 | 0 | 8mo | -3.7% | $103.5M | 34.8% | ||||
Score Breakdown Patents: 0/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 3/3 Financials Revenue: $536.0M Cash: $16.8M FCF: $-3.6M ROE: 283.8% • D/E: 100% Profit Margin: 12.7% Quality High ROE
FCF insufficient_data | ||||||||||
| SUPX | 3/12 | 0 | 16mo | - | $223.1M | 28.2% | ||||
Score Breakdown Patents: 0/3 •
Runway: 1/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $20.3M Cash: $98.9M FCF: $-107.3M ROE: -103.8% • D/E: 2% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Red Flags SBC_HIGH (167% of revenue) | ||||||||||
| BTQ | 3/12 | 1 | 5mo | - | $210.3M | 35.0% | ||||
Score Breakdown Patents: 1/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $9.8M FCF: $-3.0M ROE: -489.2% • D/E: 6% Profit Margin: N/A Quality Low Debt
FCF insufficient_data Patents (1) • Non-volatile storage of secure data in 6T SRAM cells using hot carrier injection Red Flags HYPE_PRICING ($0.0M rev, $210M mcap) | ||||||||||
| GALT | 2/12 | 0 | 10mo | - | $307.6M | 52.6% | ||||
Score Breakdown Patents: 0/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $0.0M Cash: $13.3M FCF: $-14.9M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags HYPE_PRICING ($0.0M rev, $308M mcap) | ||||||||||
| VIVO | 2/12 | 0 | 0mo | - | $71.3M | 39.9% | ||||
Score Breakdown Patents: 0/3 •
Runway: 0/3 •
Revenue: 1/3 •
Mgmt: 1/3 Financials Revenue: $2.5M Cash: $0.1M FCF: $38.9M ROE: -185.9% • D/E: 190% Profit Margin: N/A Quality FCF+
FCF insufficient_data Red Flags SBC_HIGH (1837% of revenue) | ||||||||||
| GCTS | 1/12 | 0 | 10mo | -17.9% | $116.2M | 11.6% | ||||
Score Breakdown Patents: 0/3 •
Runway: 0/3 •
Revenue: 0/3 •
Mgmt: 1/3 Financials Revenue: $4.1M Cash: $30.2M FCF: $-26.9M ROE: N/A • D/E: N/A Profit Margin: N/A Quality FCF insufficient_data Red Flags SBC_HIGH (369% of revenue) | ||||||||||
30 stocks auto-rejected (red flags)
EVTL
reverse_split
ARQQ
reverse_split
SPCE
reverse_split
VELO
reverse_split
KULR
reverse_split
ALIT
reverse_split
SENS
reverse_split
NRXP
reverse_split
AGEN
reverse_split
DTIL
reverse_split
GOSS
reverse_split
RIGL
reverse_split
LYEL
reverse_split
MNPR
reverse_split
MYPS
reverse_split
SABS
reverse_split
BNED
reverse_split
XFOR
reverse_split
COOK
reverse_split
DPRO
reverse_split
YSG
reverse_split
GDEV
reverse_split
SRZN
reverse_split
IBIO
reverse_split
TNXP
reverse_split
DVLT
reverse_split
NGNE
reverse_split
ASMB
reverse_split
GRRR
reverse_split
SIDU
reverse_split
Disclaimer: Micro cap stocks are inherently risky. This screener identifies innovation signals — it is not a buy recommendation. Always do your own due diligence. See our 7-step risk assessment methodology and full disclaimer.